# Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Canonical URL: https://biopharmsignal.com/news/PSNL/personalis-enables-global-biopharma-support-with-ce-ivd-marked-specimen-collection-kits
Ticker: PSNL
Company: Personalis
Source: Personalis
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.personalis.com
## Summary

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs FREMONT, Calif. --(BUSINESS WIRE)--Jun. 9, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision

## Article Body
Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs FREMONT, Calif. --(BUSINESS WIRE)--Jun. 9, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision
## Recent Company News
- 2026-06-25 13:46 EST — [Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits](https://biopharmsignal.com/news/PSNL/personalis-enables-global-biopharma-support-with-ce-ivd-marked-specimen-collection-kits) — Source: Personalis
- 2026-06-25 13:46 EST — [Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026](https://biopharmsignal.com/news/PSNL/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026) — Source: Personalis
- 2026-06-25 13:46 EST — [Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium](https://biopharmsignal.com/news/PSNL/personalis-to-highlight-breadth-of-next-personalr-ultra-sensitive-ctdna-data-at-asco-2026-annual-meeting-including-podium-presentation-from-tracerx-consortium) — Source: Personalis
- 2026-06-25 13:46 EST — [Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring](https://biopharmsignal.com/news/PSNL/personalis-secures-fourth-medicare-coverage-decision-for-next-personalr-expanding-breast-cancer-coverage-to-pre-surgical-treatment-monitoring) — Source: Personalis
- 2026-06-25 13:46 EST — [Personalis to Participate in Upcoming Investor Events](https://biopharmsignal.com/news/PSNL/personalis-to-participate-in-upcoming-investor-events) — Source: Personalis
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)